Literature DB >> 15596832

CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.

Janina Q Jiang1, Amy Patrick, Ronald B Moss, Kenneth L Rosenthal.   

Abstract

Human immunodeficiency virus (HIV) is a mucosally transmitted infection that rapidly targets and depletes CD4+ T cells in mucosal tissues and establishes a major reservoir for viral persistence in gut-associated lymphoid tissues. Therefore, vaccines designed to prevent HIV infections must induce potent and durable mucosal immune responses, especially in the genital tract. Here we investigated whether intranasal (i.n.) immunization with inactivated gp120-depleted HIV-1 antigen (Ag) plus CpG oligodeoxynucleotide (ODN) as an adjuvant induced local immune responses in the genital tract and cross-clade protection against intravaginal (IVAG) challenge. Lymphocytes isolated from the iliac lymph nodes (ILNs) and genital tracts of female mice i.n. immunized with HIV-1 Ag plus CpG showed significant HIV-specific proliferation and produced significantly higher levels of gamma interferon (IFN-gamma) and beta-chemokines than mice immunized with HIV-1 Ag alone or mixed with non-CpG ODN. CD8+ lymphocytes were dramatically increased in the genital tracts of mice immunized with HIV-1 Ag plus CpG, and protection following IVAG challenge with recombinant vaccinia viruses (rVVs) expressing HIV-1 gag was shown to be CD8 dependent. Finally, cross-clade protection was observed between clades A, C, and G but not B following IVAG challenge with rVVs expressing HIV-1 gag from different clades. These studies provide evidence that mucosal (i.n.) immunization induced strong local T-cell-mediated immune responses in the genital tract and cross-clade protection against IVAG challenge.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15596832      PMCID: PMC538685          DOI: 10.1128/JVI.79.1.393-400.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection.

Authors:  S McAdam; P Kaleebu; P Krausa; P Goulder; N French; B Collin; T Blanchard; J Whitworth; A McMichael; F Gotch
Journal:  AIDS       Date:  1998-04-16       Impact factor: 4.177

3.  Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

Authors:  G Ferrari; W Humphrey; M J McElrath; J L Excler; A M Duliege; M L Clements; L C Corey; D P Bolognesi; K J Weinhold
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant.

Authors:  D J Choi; S Dube; T P Spicer; H B Slade; F C Jensen; B J Poiesz
Journal:  AIDS Res Hum Retroviruses       Date:  1997-03-01       Impact factor: 2.205

5.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.

Authors:  R S Veazey; M DeMaria; L V Chalifoux; D E Shvetz; D R Pauley; H L Knight; M Rosenzweig; R P Johnson; R C Desrosiers; A A Lackner
Journal:  Science       Date:  1998-04-17       Impact factor: 47.728

6.  HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.

Authors:  S Mazzoli; D Trabattoni; S Lo Caputo; S Piconi; C Blé; F Meacci; S Ruzzante; A Salvi; F Semplici; R Longhi; M L Fusi; N Tofani; M Biasin; M L Villa; F Mazzotta; M Clerici
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

7.  CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL.

Authors:  A K Yi; P Hornbeck; D E Lafrenz; A M Krieg
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

8.  Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization.

Authors:  W S Gallichan; K L Rosenthal
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

9.  Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2.

Authors:  Amanda Kwant; Kenneth L Rosenthal
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

10.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

View more
  17 in total

1.  Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag.

Authors:  Xinyan Zhao; Manxin Zhang; Zhongxia Li; Fred R Frankel
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.

Authors:  Wing-pui Kong; Ling Xu; Konrad Stadler; Jeffrey B Ulmer; Sergio Abrignani; Rino Rappuoli; Gary J Nabel
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Qualitative and quantitative characteristics of rotavirus-specific CD8 T cells vary depending on the route of infection.

Authors:  Janina Q Jiang; Xiao-Song He; Ningguo Feng; Harry B Greenberg
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

Review 4.  Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Expert Opin Biol Ther       Date:  2010-08       Impact factor: 4.388

Review 5.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

6.  Isolation of lymphocytes from mouse genital tract mucosa.

Authors:  Janina Jiang; Kathleen A Kelly
Journal:  J Vis Exp       Date:  2012-09-03       Impact factor: 1.355

7.  Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.

Authors:  Loane Decrausaz; Sonia Domingos-Pereira; Mélanie Duc; Martine Bobst; Pedro Romero; John T Schiller; Patrice Jichlinski; Denise Nardelli-Haefliger
Journal:  Int J Cancer       Date:  2011-08-01       Impact factor: 7.396

8.  Tweaking Innate Immunity: the Promise of Innate Immunologicals As Anti-infectives.

Authors:  Kenneth L Rosenthal
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

9.  Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes.

Authors:  Mariana Manrique; Pamela A Kozlowski; Antonio Cobo-Molinos; Shainn-Wei Wang; Robert L Wilson; David C Montefiori; Angela Carville; Anna Aldovini
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

10.  Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization.

Authors:  Waleed Mustafa; Paulo Cesar Maciag; Zhen-kun Pan; Jessica R Weaver; Yuhong Xiao; Stuart N Isaacs; Yvonne Paterson
Journal:  Viral Immunol       Date:  2009-06       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.